Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like

Related Experiment Video

Updated: May 10, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Da-Liang Ou1, Bin-Shyun Lee, Ya-Chi Chang

  • 1Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.

Plos One
|July 3, 2013
PubMed

Insights

Combining insulin-like growth factor receptor (IGFR) inhibition with targeted therapies shows promise for hepatocellular carcinoma (HCC). IGFR inhibition enhances sunitinib

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The insulin-like growth factor (IGF) signaling pathway plays a crucial role in cancer development and drug resistance.
  • Hepatocellular carcinoma (HCC) is a major global health concern with limited effective treatment options.

Purpose of the Study:

  • To investigate the synergistic effects of inhibiting the IGF receptor (IGFR) in combination with molecular targeted agents (MTAs) in HCC.
  • To evaluate the potential of this combination therapy to overcome drug resistance and enhance anti-tumor activity.

Main Methods:

  • Utilized HCC cell lines (Hep3B, PLC5, SK-Hep1) and HUVECs for in vitro studies.
  • Tested molecular targeted agents including sorafenib, sunitinib, and the IGFR kinase inhibitor NVP-AEW541.
  • Assessed synergistic antitumor effects using median dose effect analysis, apoptosis assays, xenograft models, RNA interference, and Western blotting.

Main Results:

  • IGF activates IGFR and AKT signaling in HCC cells, with the most prominent growth stimulation observed in Hep3B cells.
  • NVP-AEW541 effectively blocked IGF-induced IGFR and AKT activation.
  • Combination of IGFR inhibition (NVP-AEW541 or IGFR knockdown) with sunitinib significantly enhanced apoptosis and anti-tumor effects in HCC cells, an effect mediated by Chk2 kinase activation.
  • Sorafenib did not show enhanced apoptosis when combined with IGFR inhibition.

Conclusions:

  • IGFR inhibition potentiates the anti-tumor effects of specific molecular targeted agents, like sunitinib, in HCC.
  • The efficacy of IGFR inhibition in combination therapy is drug-specific.
  • Combination therapy involving IGFR inhibitors and other MTAs holds potential for improving therapeutic outcomes in HCC.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...